Skip to content
BioPorto_Logo
BioPorto_Logo
Bioporto Diagnostics_logo

 

AKI & NGAL+           PRODUCTS+          ABOUT+        CONTACT+

 

 

 

 

The NGAL biomarker

Early Clinical Decision Support for AKI

The NGAL Test for Early Diagnosis of AKI

Acute kidney injury (AKI) plagues critically ill patients and goes undiagnosed in up to 75% cases1. This results in prolonged hospitalization, increased reliance on renal replacement therapies (RRT), and chronic health issues. The NGAL biomarker identifies AKI 2-3 hours following injury2 compared to serum creatinine (SCr), the current diagnostic standard of care, which can take 2 to 3 days to increase3 to abnormal ranges before it's flagged as an issue. SCr, which is insensitive and delayed, can miss cases of AKI.

Addressing the Gap in the Clinician’s Toolkit for AKI

The primary biomarker for AKI, as per Kidney Disease Improving Global Outcomes (KDIGO) criteria, is serum creatinine (SCr). SCr only detects functional injury, not structural damage. In contrast, the NGAL biomarker (neutrophil gelatinase-associated lipocalin) detects structural injury, which can be identified before functional damage.

Recognizing the gap in the 2012 KDIGO guidelines4, the ADQI recommendations5 now include structural biomarkers like NGAL to better phenotype AKI.

body image (2)

To help us connect you with an appropriate peer, please complete this form

Connect with a peer about the benefits of NGAL
body image (8)

The NGAL Test Provides Early Clinical Decision Support for AKI

The NGAL Test™ is CE-Marked for IVD use throughout the European Union. In conjunction with clinical evaluation, The NGAL Test can help diagnose AKI within 2-3 hours of structural damage, through assessment of the NGAL biomarker (neutrophil gelatinase-associated lipocalin) levels in plasma and urine.2 The NGAL Test provides clinicians with the power of earlier intervention and ultimately, improved patient outcomes.


The NGAL Test is a quantitative immunoassay that analyzes urine and plasma on standard clinical chemistry analyzers using particle-enhanced turbidimetry.


Choose The NGAL Test for actionable results.

Learn more about The NGAL Test and its clinical utility

References:

1Weiss R, Meersch M, Pavenstadt HJ, Zarbock A ‘Acute kidney injury - a frequently underestimated problem in perioperative medicine. Dtsch Arztebl Int 2019; 116: 833-842 DOI:10.3238/arztebl.2019.0833.

2Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011.

3Devarajan P. Review: Neutrophil gelatinase‐associated lipocalin: A troponin‐like biomarker for human acute kidney injury. Nephrology. 2010.

4KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Kidney International, Suppl. 2012;2:1-138.

5Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney International. 2020;98(2):294-309.